The European Medicines Agency warns that Novo Nordisk's Ozempic and Wegovy may, in rare cases, cause NAION—a serious eye condition that can lead to vision loss. The EMA has asked the company to update ...

These five Dow Jones industrial companies have paid dividends to shareholders for at least 100 years, perfect ideas for ...

Weight-loss drugs are already dropping in price; could they go even lower? - Consumers are now able to pay roughly $500 for ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic ...